From April 2026, GPs in England can prescribe Mounjaro for obesity as part of their NHS contract for the first time. But there are important conditions attached — and not every patient who qualifies will automatically get it. Here is what you actually need to know.
If you have been waiting for Mounjaro on the NHS, April 2026 brought the most significant shift yet. NHS England confirmed that tirzepatide — the active ingredient in Mounjaro — will now feature in the GP contract for 2026 to 2027. That means GPs in England are, for the first time, formally supported to prescribe it as part of their everyday NHS work. [NHS England / NICE, 1 April 2026]
Before this change, most people accessing Mounjaro in the UK were paying privately — often hundreds of pounds a month. This update is a genuine step forward. But it comes with conditions that are worth understanding before you get your hopes up.
How the new GP contract actually works
The change sits within something called the Quality and Outcomes Framework, or QOF for short. This is the system NHS England uses to set targets for GP practices and reward them financially for hitting those targets. [NHS England / NICE, 1 April 2026]
Crucially, participation is optional. Your GP practice does not have to sign up. Some practices, particularly smaller ones or those with limited staff, may choose not to take part at all. So the postcode lottery that has defined obesity treatment on the NHS has not disappeared overnight.
Even if your practice does participate, meeting the eligibility criteria does not guarantee you will receive treatment. The wording from NHS England is clear on this point. Eligibility gets you through the door. It does not hand you a prescription. [NHS England / NICE, 1 April 2026]
Eligibility is expected to follow the criteria already established by NICE — the National Institute for Health and Care Excellence, the body that decides which treatments the NHS funds. That broadly means a BMI of 35 or above, plus at least one weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. Some people with a BMI of 30 or above may also qualify depending on their circumstances.
The behavioural support condition
This is the part that many headlines have glossed over. Mounjaro on the NHS will not be handed out as a standalone prescription. NHS England has made wraparound behavioural support a condition of prescribing. [NHS England / NICE, 1 April 2026]
Wraparound support means structured help with eating habits, physical activity, and the psychological side of weight management. Think of it as the coaching that sits alongside the medication. The drug does the heavy lifting on appetite, but the support helps you build habits that last beyond the prescription.
This mirrors the approach taken in clinical trials, where participants received dietary and lifestyle guidance alongside the medication. In those trials, tirzepatide produced an average weight loss of around 20 percent of body weight over 72 weeks. [SURMOUNT-1 trial, New England Journal of Medicine, 2022]
The practical question is whether GP practices have the capacity to deliver that support, or commission it locally. In some areas, NHS tier 3 weight management services — specialist teams that provide exactly this kind of structured programme — already exist. In others, provision is thin. Again, where you live matters enormously.
What this means if you are currently paying privately
If you are already on Mounjaro through a private provider, this announcement does not automatically move you onto NHS treatment. You would need to approach your GP practice, check whether they are participating in the new QOF indicators, and go through the eligibility and referral process from scratch.
It is also worth knowing that private prescriptions for GLP-1 medicines — the class that includes Mounjaro and Ozempic — do not always appear in your NHS records. The MHRA flagged this as a patient safety concern in January 2026, urging clinicians to ask patients directly about any privately prescribed weight loss injections. [MHRA, 29 January 2026] If you are moving between private and NHS care, be transparent with every prescriber about what you are taking.
There is also the question of continuity. Moving from a private provider to NHS prescribing may involve switching dose, changing injection schedule, or pausing treatment while you wait for an appointment. Stopping a GLP-1 medication abruptly can lead to weight regain. Talk to your current prescriber before making any changes.
When will this actually affect patients?
The contract change applies from April 2026. However, the reality of NHS implementation means that changes filter through at different speeds in different parts of England. Some practices will move quickly. Others will take months to update their systems, train staff, and commission the required behavioural support services.
If you want to know where your practice stands, the most direct approach is to contact your GP surgery and ask whether they are participating in the new obesity QOF indicators for 2026 to 2027. A simple, polite phone call or online message is all it takes.
Wales, Scotland, and Northern Ireland operate their own NHS structures and are not covered by NHS England’s GP contract. If you live outside England, the rules are different and you should check with your own GP or health board for current guidance.
The bigger picture
The arrival of Mounjaro on the NHS through the GP contract is genuinely meaningful progress. For years, access to the most effective weight loss medicines has depended on your ability to pay. A private prescription for tirzepatide can cost anywhere from £150 to over £250 a month — money that most people simply do not have.
Bringing Mounjaro on the NHS into routine GP care, even gradually and imperfectly, shifts the conversation. It signals that obesity is a medical condition that deserves treatment — not a lifestyle failure that deserves a lecture.
But managed expectations matter. Optional participation, eligibility criteria, mandatory support conditions, and real-world capacity pressures mean that access will remain uneven for some time. The announcement is a foundation, not a finished building.
Watch this space. We will update this article as more GP practices confirm participation and as the picture becomes clearer across different regions of England.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
